Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220311 | 0.82 | PLAU (0.52) | PLGPLAUEPHX2ALOX5HDAC8 | |
| SCHEMBL220832 | 0.80 | PLG (0.48) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL218188 | 0.79 | PLG (0.49) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL221760 | 0.77 | PLA2G4A (0.49) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL4075945 | 0.77 | OPRM1 (0.57) | OPRM1OPRD1OPRK1EPHX2 | |
| SCHEMBL218880 | 0.77 | OPRM1 (0.48) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL222138 | 0.76 | OPRM1 (0.50) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL219690 | 0.76 | HDAC6 (0.60) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL219684 | 0.76 | OPRM1 (0.53) | OPRM1OPRD1OPRK1PLGPLAU | |
| SCHEMBL221602 | 0.74 | EPHX2 (0.51) | OPRM1OPRD1OPRK1EPHX2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | claimed |
| EP-1751103-B1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | LILLY CO ELI (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | claimed |
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1751103-B1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | LILLY CO ELI (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1751103-B1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | LILLY CO ELI (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| EP-1751103-A1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005090303-A1 | 4- (5- (AMINOMETHYL) -INDOLE-1-YLMETHYL) -BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.